Surveyed EU5 Oncologists Plan Increased Uptake of Perjeta for HER2-Positive Breast Cancer, But Expect Reimbursement Hurdles for

 Surveyed EU5 Oncologists Plan Increased Uptake of Perjeta for HER2-Positive
  Breast Cancer, But Expect Reimbursement Hurdles for Perjeta Plus Kadcycla

Interviewed Payers Indicate that Budget Constraints May Also Drive Uptake of
Trastuzumab Biosimilars over Branded Herceptin, According to a New Report from
Decision Resources

PR Newswire

BURLINGTON, Mass., Nov. 7, 2013

BURLINGTON, Mass., Nov. 7, 2013 /PRNewswire/ --Decision Resources, one of the
world's leading research and advisory firms for pharmaceutical and healthcare
issues, finds that surveyed medical oncologists across the EU5 (France,
Germany, Italy, Spain and the United Kingdom) currently prescribe
Roche/Genentech's targeted agent Herceptin (with or without chemotherapy
and/or hormonal therapy) to an average of half or more of their first-line
HER2+ advanced breast cancer patients. Considering likely funding or
reimbursement restrictions, respondents expect their prescribing of
Roche/Genentech's Perjeta—which was approved in March 2013—in combination 
with Herceptin, will increase substantially from an average of no more than 12
percent of such patients currently to around one-quarter of patients in most
countries by the end of 2016.


The new European Physician and Payer Forum report entitled Tightening
Healthcare Budgets and Elevated Cost-Effectiveness Expectations: How Will
Payers and Prescribers Prioritize Targeted Agents for Breast Cancer in the
EU5? also finds that although half or more surveyed oncologists expect that
Roche/Genentech's emerging HER2-targeting antibody drug conjugate Kadcyla in
combination with Perjeta will likely demonstrate a significant efficacy
benefit over single agent Kadcyla or Herceptin with chemotherapy in the
advanced HER2+ first-line setting, less than 40 percent of respondents across
the EU5 expect premium-priced Kadcyla/Perjeta combination is likely to be
reimbursed in their country or region. Collectively, those surveyed anticipate
that less than 10 percent of their first-line HER2+ advanced breast cancer
patients will receive this combination by the end of 2016, highlighting
evolving reimbursement and funding constraints as a major hurdle in achieving
optimal uptake for emerging therapies.

The report also emphasizes interviewed EU5 payers' perspectives on the
importance of high-cost therapies directly demonstrating a benefit in overall
survival over a suitable comparator in order to justify their premium price
tag. Interviewed payers stress that for HER2-targeted agents in particular,
clinical trial design and efficacy outcomes will be subject to greater
scrutiny in health technology assessments as this drug class becomes more
crowded, owing to anticipated approvals of novel therapies and the emergence
of trastuzumab biosimilars.

"Drug developers need to have effective marketing strategies which demonstrate
the main advantages and long-term benefits of treatment with novel targeted
therapies to encourage payers and prescribers to look beyond their high cost,"
said Decision Resources Senior Business Insights Analyst Gemma McConnell.
"Increasing competition between current and emerging HER2-targeted therapies
and the anticipated entry of less expensive biosimilar trastuzumab amid
tightening healthcare budgets make such strategies particularly important in
this market segment."

About Decision Resources
Decision Resources ( is a world leader in market
research publications, advisory services and consulting designed to help
clients shape strategy, allocate resources and master their chosen markets.
Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources Group at

All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.

SOURCE Decision Resources

Contact: Decision Resources Group, Christopher Comfort, 781-993-2597,
Press spacebar to pause and continue. Press esc to stop.